<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <Volume-Issue>Volume 12, Issue 4</Volume-Issue>
      <Season>October- December, 2020</Season>
      <ArticleTitle>A comparative study of the in vitro antioxidant activity of dipeptidyl peptidase-4 inhibitors</ArticleTitle>
      <Abstract>In vitro antioxidant activity assay is the preliminary step to determine a drug’s efficacy in combating oxidative stress when used in a clinical condition. Oxidative stress is a major concern in disease like diabetes mellitus where elevated level of glucose leads to higher generation of free radicals. The current study was aimed to determine the in vitro antioxidant activity of antidiabetic drug-the dipeptidyl peptidase-4 inhibitor (sitagliptin, vildagliptin, and saxagliptin) in combating the oxidative stress in diabetes mellitus. A total of five methods were adopted for determining the antioxidant potential of the drugs. The methods were 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay, nitric oxide (NO), radical scavenging assay, phosphomolybdenum assay, assessment of inhibition of lipid peroxidation, and potassium ferricyanide mediated ferric reduction activity potential (PFRAP). The results indicated vildagliptin as best DPPH radical scavenger and saxagliptin as the best scavenger of NO radicals. Sitagliptin showed best reducing power and saxagliptin and sitagliptin showed promising results in inhibiting lipid peroxidation. These findings suggest that use of sitagliptin and saxagliptin in diabetic patient may control the hyperglycemic conditions well as other complications that are caused by hyperglycemia induced oxidative stress.</Abstract>
      <Keywords>2,2-diphenyl-1-picrylhydrazyl, FRAP, Lipid peroxidation, Phosphomolybdenum assay</Keywords>
        <Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=13811&amp;title=A comparative study of the in vitro antioxidant activity of dipeptidyl peptidase-4 inhibitors</Abstract>
        <References>1. Dicker D. DPP-4 inhibitors: Impact on glycemic control and cardiovascular risk factors. Diabetes Care 2011;34:276-8.&#13;
2. Rucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705.&#13;
3. Pathak R, Bridgeman MB. Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes. Pharm Ther 2010;35:509-13.&#13;
4. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60:1454-70.&#13;
5. Sharpe PC, Yue KK, Catherwood MA, McMaster D, Trimble ER. The effects of glucose-induced oxidative stress on growth and extracellular matrix gene expression of vascular smooth muscle cells. Diabetologia 1998;41:1210-9.&#13;
6. Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical practice. Cardiovasc Diabetol 2005;4:5.&#13;
7. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058-70.&#13;
8. Takahara N, Kashiwagi A, Nishio Y. Oxidized lipoproteins found in patients with NIDDM stimulate radical-induced monocyte chemoattractant protein-1 mRNA expression in cultured human endothelial cells. Diabetologia 1997;40:662-70.&#13;
9. Nishio Y, Kashiwagi A, Taki H. Altered activities of transcription factors and their related gene expression in cardiac tissues of diabetic rats. Diabetes 1998;47:1318-25.&#13;
10. De A, Chattopadhyay P, Singh M. In-vitro antioxidant activity and free radical scavenging potential of phlorizin derived sodium glucose cotransporter 2 inhibitor. J Drug Deliv Ther 2019;9:257-64.&#13;
11. Prieto P, Pineda M, Aguilar M. Spectrophotometric quantification of antioxidant capacity through the formation of a phosphomolybdenum complex: Specific application to the determination of Vitamin E. Anal Biochem 1999;269:337-41.&#13;
12. Roberto G, Baratta MT. Antioxidant activity of selected essential oil components in two lipid model systems. Food Chem 2000;69:167-74.&#13;
13. Bajpai VK, Sharma A, Kang SC, Baek KH. Antioxidant, lipid peroxidation inhibition and free radical scavenging efficacy of a diterpenoid compound sugiol isolated from Metasequoia glyptostroboides. Asian Pac J Trop Med 2014;9:9-15.&#13;
14. De A, Singh M, Chattopadhyay P. In-vitro ant?ox?dant capac?ty and free rad?cal scavenging activity of var?ous anti depressant drugs. Indo Am J Pharm Res 2018;8:1343-56.&#13;
15. Stadtman ER. Protein oxidation and aging. Science 1992;257:1220-4.&#13;
16. Chang LW, Yen WJ, Huang SC, Duh PD. Antioxidant activity of sesame coat. Food Chem 2002;78:347-54.&#13;
17. Dey P, Chaudhuri D, Chaudhuri TK, Mandal N. Comparative assessment of the antioxidant activity and free radical scavenging potential of different parts of Nerium indicum. Int J Phytomed 2012;4:54-69.&#13;
18. Fang YZ, Yang S, Wu G. Free radicals, antioxidants, and nutrition. Nutrition 2002;18:872-9.&#13;
19. Noguchi N, Niki E. Chemistry of oxygen species and antioxidants. In: PapasAM, editor. Antioxidant Status, Diet, Nutrition, and Health. Boca Raton: CRC Press; 1993. p. 3-20.&#13;
20. Miller MJ, Sadowska-Krowicka H, Chotinaruemol S, Kakkis JL, Clark DA. Amelioration of chronic ileitis by nitric oxide synthase inhibition. J Pharmacol Exp Ther 1993;264:11-6.&#13;
21. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharm Rev 1991;43:109-42.&#13;
22. Marcocci PL, Sekaki A, Gardand;egrave;s-Albert M. Antioxidant action of Ginkgo biloba extract EGb 761. Methods Enzymol 1994;234:462-75.&#13;
23. Braca A, Sortino C, Politi M, Morelli I, Mendez J. Antioxidant activity of flavonoids from Licania licaniaeflora. J Ethnopharmacol 2001;79:379-81.</References>